Biocorp s’introduit sur Alternext Paris

Back

Paris – 10 July 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for small and medium-sized companies (SMEs),today celebrated the listing of Biocorp, a French company specialised in developing and manufacturing innovative medical and drug delivery devices. Biocorp is listed on Alternext Paris.

Biocorp is a French company that develops, manufactures and markets innovative medical devices for the pharmaceutical industry. Based in Issoire, near Clermont-Ferrand in central France, Biocorp was founded in 2004 and has been awarded BIP’s “Innovative Company” label. From the start, it has combined production of devices for leading pharmaceutical players—generating a stream of recurring income—with active R&D in medical devices, in particular seal and reconstitution systems. At the instigation of founder Jacques Gardette, Biocorp acquired a software/data encryption and management business in 2013 to develop the very first connected injection systems. Its first product is DataPen, the first smart injector pen connected to the internet, whose prime market is the treatment of diabetes.

Biocorp (ticker code: ALCOR) was listed through the admission to trading on 10 July 2015 of the 2,957,867 ordinaryshares making up its equity, including 957,867new shares issued through a Global Offering.

The admission and issue price of Biocorp shares was set at €9.25per share. Market capitalisation was around €27,360,270on the day of listing, and the total amount raised was €8,860,270million.

Jacques Gardette, Biocorp’s founder, chairman & CEO, said:“Our successful listing gives us the resources we need to deploy our strategy quickly and achieve several critical milestones, including new contracts, expansion on international markets and a ramp-up of production capacity. Listing will also raise our profile and facilitate agreements with international partners. I would like to thank all of our employees and partners, along with our new shareholders, for their confidence.”

Eric Forest, CEO of EnterNext, said: “We are delighted to welcome Biocorp, a medtech company based in Auvergne, as it lists on Alternext. EnterNext has helped many medtech businesses secure the funding they need through financial markets to accelerate their business development. Listing will give Biocorp resources to beef up its R&D, which is at the core of its business, and to ramp up its production capacity. Biocorp is the 23rd SME IPO on our markets in 2015, confirming investor appetite for medium sized companies since the beginning of the year.

 

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.